Howard A. Kelly

Researcher

Last publication 2024 Last refreshed 2026-05-16

faculty

11 h-index 141 pubs 1,002 cited

Biography and Research Information

OverviewAI-generated summary

Howard A. Kelly's research focuses on gynecological health, with recent work investigating therapeutic vaccines for cervical intraepithelial neoplasia (CIN2/3). This includes a Phase 2 clinical trial for PepCan, a peptide-based human papillomavirus (HPV) therapeutic vaccine, and a comparison with Candida adjuvant alone. Kelly has also explored the use of virtual reality technology to manage patient anxiety and reduce opioid use during brachytherapy procedures for gynecological cancer patients. His scholarly contributions are reflected in a h-index of 11, with 141 total publications and over 1,000 citations. He has collaborated with researchers such as Charles M. Quick, David W. Ussery, Michael S. Robeson, and William W. Greenfield at the University of Arkansas for Medical Sciences, co-authoring multiple publications with each.

Metrics

  • h-index: 11
  • Publications: 141
  • Citations: 1,002

Selected Publications

  • A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
    3 citations DOI OpenAlex
  • GSOR03 Presentation Time: 5:10 PM (2024)
  • A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
    2 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

9 Collaborators 3 Institutions 1 Country

Top Collaborators

View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics